Therapeutic targeting of cancers with loss of PTEN function

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a critical tumor suppressor frequently altered in various cancers.
• PTEN's lipid phosphatase activity inhibits the PI3K/AKT/mTOR pathway, suppressing tumor cell proliferation and survival.
• Nuclear PTEN function is vital for maintaining genomic stability and facilitating DNA repair.

Purpose of the Study:

• To review current therapeutic strategies for cancers with PTEN loss-of-function.
• To discuss the challenges associated with treating PTEN-deficient tumors.
• To highlight emerging therapeutic approaches targeting PTEN-deficient cancers.

Main Methods:

• Review of preclinical and clinical findings on PTEN-deficient cancers.
• Analysis of mechanisms underlying PTEN deficiency (mutations, epigenetic silencing, etc.).
• Exploration of therapeutic strategies targeting PTEN loss.

Main Results:

• PTEN deficiency leads to increased genomic instability and uncontrolled cell growth.
• Various mechanisms contribute to PTEN loss across cancer types.
• Targeting PTEN-deficient cancers presents unique therapeutic opportunities and challenges.

Conclusions:

• Effective therapeutic strategies for PTEN-deficient cancers are urgently needed.
• Novel approaches are under development to exploit PTEN loss-of-function for cancer treatment.
• Further research is crucial to overcome challenges in treating these aggressive cancers.